Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q5T160
UPID:
SYRM_HUMAN
Alternative names:
Arginyl-tRNA synthetase
Alternative UPACC:
Q5T160; B2RDT7; Q96FU5; Q9H8K8
Background:
The Probable arginine--tRNA ligase, mitochondrial, also known as Arginyl-tRNA synthetase, plays a crucial role in protein synthesis by attaching arginine to its corresponding tRNA. This process is vital for the translation of genetic information into functional proteins.
Therapeutic significance:
Pontocerebellar hypoplasia 6, a severe neurological disorder, is linked to mutations in the gene encoding this protein. Understanding the role of Probable arginine--tRNA ligase, mitochondrial could open doors to potential therapeutic strategies.